Hutchmed (HCM) said Monday that the China National Medical Products Administration has approved its new drug application for the combination of Orpathys and Tagrisso to treat a certain type of lung cancer.
The approval covers locally advanced or metastatic epidermal growth factor receptor mutation-positive non-squamous non-small cell lung cancer with MET amplification after disease progression on EGFR tyrosine kinase inhibitor therapy.
The company said the approval triggers an $11 million milestone payment from AstraZeneca (AZN), which markets both the drugs in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.